2025 Q4 -tulosraportti
45 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sittenThe stock is at 1.15kr. What is it you don't understand? Tomorrow the hearing is over. What we should expect to happen subsequently is. That those designated as spokespersons will go out to scientific media, and inform which areas receive a 1st degree recommendation, as the committee agrees on it. In this way, the committee gradually prepares the affected areas (plural), who will be affected by the 1st degree recommendation, for by this approach, they hope to avoid bottlenecks when the affected areas worldwide order NGAL tests all at once, The treatment centers that already have the machines can simply order NGAL tests, and it will be a plug and play solution, but those who also need to invest in a machine will have the opportunity to do so, at their leisure. When they do it this way, it's because the committee is aware that Bioporto cannot have a huge, overflowing stock of NGAL tests and be ready to send them out to the affected areas worldwide at the same time. This is the reason why the committee will gradually go out and inform which areas they have decided will receive a 1st degree recommendation. The final finished document, we must expect, will only come out in a few months, because they want to be absolutely sure that it is crystal clear which areas are affected by the 1st degree recommendation, and which are affected by the 2nd degree recommendation, because they do not want to risk the text being interpreted in one way or another. When KDIGO comes with a recommendation about this and that, then everyone affected by their recommendation, WORLDWIDE, will click their heels together and say "yes sir", and fall into line and do as they recommend. What is it you don't understand?- ·1 päivä sittenBioPorto – Presentation of Q1 2026 results https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·1 päivä sittenThe devil is in the detail. If we look at what Bioporto wrote 2 weeks ago, before KDIGO's recommendation, which will be significant for Bioporto, was blown up here on Nordnet social, CB and KW came with a guidance that if they had 60 hospitals by the end of 2026, then the goal was reached. See the link. Now CB and KW have, in silence, changed this to 60+ hospitals. You can read this in the presentation for the next webcast. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
·2 päivää sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·3 t sittenBager Darn it. Here one thought you were going directly for course 4, which you otherwise spent a lot of time explaining to us :)
2 päivää sitten2 päivää sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.- ·2 päivää sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
45 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenThe stock is at 1.15kr. What is it you don't understand? Tomorrow the hearing is over. What we should expect to happen subsequently is. That those designated as spokespersons will go out to scientific media, and inform which areas receive a 1st degree recommendation, as the committee agrees on it. In this way, the committee gradually prepares the affected areas (plural), who will be affected by the 1st degree recommendation, for by this approach, they hope to avoid bottlenecks when the affected areas worldwide order NGAL tests all at once, The treatment centers that already have the machines can simply order NGAL tests, and it will be a plug and play solution, but those who also need to invest in a machine will have the opportunity to do so, at their leisure. When they do it this way, it's because the committee is aware that Bioporto cannot have a huge, overflowing stock of NGAL tests and be ready to send them out to the affected areas worldwide at the same time. This is the reason why the committee will gradually go out and inform which areas they have decided will receive a 1st degree recommendation. The final finished document, we must expect, will only come out in a few months, because they want to be absolutely sure that it is crystal clear which areas are affected by the 1st degree recommendation, and which are affected by the 2nd degree recommendation, because they do not want to risk the text being interpreted in one way or another. When KDIGO comes with a recommendation about this and that, then everyone affected by their recommendation, WORLDWIDE, will click their heels together and say "yes sir", and fall into line and do as they recommend. What is it you don't understand?
- ·1 päivä sittenBioPorto – Presentation of Q1 2026 results https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·1 päivä sittenThe devil is in the detail. If we look at what Bioporto wrote 2 weeks ago, before KDIGO's recommendation, which will be significant for Bioporto, was blown up here on Nordnet social, CB and KW came with a guidance that if they had 60 hospitals by the end of 2026, then the goal was reached. See the link. Now CB and KW have, in silence, changed this to 60+ hospitals. You can read this in the presentation for the next webcast. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
- ·2 päivää sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·3 t sittenBager Darn it. Here one thought you were going directly for course 4, which you otherwise spent a lot of time explaining to us :)
- 2 päivää sitten2 päivää sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.
- ·2 päivää sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
45 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenThe stock is at 1.15kr. What is it you don't understand? Tomorrow the hearing is over. What we should expect to happen subsequently is. That those designated as spokespersons will go out to scientific media, and inform which areas receive a 1st degree recommendation, as the committee agrees on it. In this way, the committee gradually prepares the affected areas (plural), who will be affected by the 1st degree recommendation, for by this approach, they hope to avoid bottlenecks when the affected areas worldwide order NGAL tests all at once, The treatment centers that already have the machines can simply order NGAL tests, and it will be a plug and play solution, but those who also need to invest in a machine will have the opportunity to do so, at their leisure. When they do it this way, it's because the committee is aware that Bioporto cannot have a huge, overflowing stock of NGAL tests and be ready to send them out to the affected areas worldwide at the same time. This is the reason why the committee will gradually go out and inform which areas they have decided will receive a 1st degree recommendation. The final finished document, we must expect, will only come out in a few months, because they want to be absolutely sure that it is crystal clear which areas are affected by the 1st degree recommendation, and which are affected by the 2nd degree recommendation, because they do not want to risk the text being interpreted in one way or another. When KDIGO comes with a recommendation about this and that, then everyone affected by their recommendation, WORLDWIDE, will click their heels together and say "yes sir", and fall into line and do as they recommend. What is it you don't understand?
- ·1 päivä sittenBioPorto – Presentation of Q1 2026 results https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·1 päivä sittenThe devil is in the detail. If we look at what Bioporto wrote 2 weeks ago, before KDIGO's recommendation, which will be significant for Bioporto, was blown up here on Nordnet social, CB and KW came with a guidance that if they had 60 hospitals by the end of 2026, then the goal was reached. See the link. Now CB and KW have, in silence, changed this to 60+ hospitals. You can read this in the presentation for the next webcast. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
- ·2 päivää sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·3 t sittenBager Darn it. Here one thought you were going directly for course 4, which you otherwise spent a lot of time explaining to us :)
- 2 päivää sitten2 päivää sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.
- ·2 päivää sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Dataa ei löytynyt